As previously reported, Jefferies analyst David Stanton upgraded Mesoblast (MESO) to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast upgraded to Buy from Hold at Jefferies
- Mesoblast to Launch Pivotal Ryoncil® Trial for Severe aGvHD in Adults
- Mesoblast collaborating with BMT CTN on trial of Ryoncil in acute GvHD
- Mesoblast appoints James O’Brien as CFO
- Mesoblast Announces Director’s Share Acquisition and New Equity Issuance